Department of Clinical Laboratory, Affiliated People Hospital of Fujian University of Traditional Chinese Medicine, 602 Bayiqi Road, Fuzhou, 350001, Fujian, China.
Department of Clinical Laboratory, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou, 350001, Fujian, China.
Sci Rep. 2021 Mar 22;11(1):6564. doi: 10.1038/s41598-021-85986-w.
Breast cancer (BC) is one of the most dangerous malignant diseases in females. However, the reliable serum biomarkers of BC still need to be explored. Chemerin levels have been found to be associated with different types of cancer. This study aimed to evaluate the role of serum chemerin as a biomarker of BC diagnosis, as well as the correlation between serum chemerin levels and clinicopathological features. The serum from 248 BC patients, 30 breast benign tumor patients, and 103 healthy controls were collected and serum chemerin levels were determined with enzyme-linked immunosorbent assay. We found that serum levels of chemerin in BC patients were higher than those in healthy control individuals (p < 0.05). The area under the ROC curve (AUC) for chemerin, CA15-3 and CEA was 0.703, 0.662 and 0.581, respectively, in distinguishing between breast cancer patients from healthy individuals, and the chemerin cutoff value was 100.327 ng/ml with a sensitivity of 56.60% and a specificity of 98.10%. The AUC for chemerin + CA15-3 was 0.822, which was higher than that for chemerin + CEA and CEA + CA15-3. Moreover, serum levels of chemerin were significantly associated with histologic grade, Ki67 expression, and menopausal status. However, no significant association was found between serum levels of chemerin and age, tumor size, metastase, ER status, PR status, and HER-2 status. Overall, our study suggested that the combination of chemerin with CA15-3 achieves relatively better diagnostic performance in the breast cancer. Elevated serum chemerin is associated with Ki67 expression levels and histologic grade.
乳腺癌（BC）是女性中最危险的恶性疾病之一。然而，仍需要探索可靠的血清生物标志物来诊断乳腺癌。研究发现 chemerin 水平与不同类型的癌症有关。本研究旨在评估血清 chemerin 作为 BC 诊断标志物的作用，以及血清 chemerin 水平与临床病理特征之间的相关性。收集了 248 例 BC 患者、30 例乳腺良性肿瘤患者和 103 名健康对照者的血清，用酶联免疫吸附试验测定血清 chemerin 水平。我们发现 BC 患者血清 chemerin 水平高于健康对照组（p<0.05）。在区分乳腺癌患者与健康个体时，chemerin、CA15-3 和 CEA 的 ROC 曲线下面积（AUC）分别为 0.703、0.662 和 0.581，chemerin 的截断值为 100.327ng/ml，灵敏度为 56.60%，特异性为 98.10%。chemerin+CA15-3 的 AUC 为 0.822，高于 chemerin+CEA 和 CEA+CA15-3。此外，血清 chemerin 水平与组织学分级、Ki67 表达和绝经状态显著相关。然而，血清 chemerin 水平与年龄、肿瘤大小、转移、ER 状态、PR 状态和 HER-2 状态之间无显著相关性。总之，本研究表明 chemerin 与 CA15-3 联合使用在乳腺癌的诊断中具有相对较好的诊断性能。血清 chemerin 水平升高与 Ki67 表达水平和组织学分级有关。
